# TVM Capital

> TVM Capital is a VC fund in Munich backing Biotechnology and Health Care. See 102 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Munich, Germany
- Total investments: 102
- Last investment: Feb 2023
- Lead investor: 19%
- Fund size: $290M
- Last fund: Oct 2005
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/tvm-capital
- Website: http://www.tvm-capital.com

TVM Capital is a global venture and growth capital firm that aims to finance select biopharmaceutical and medical device companies. TVM Capital was founded in 1983 and is based Munich, Bavaria.

## Contacts

5 contacts available for TVM Capital. Shizune tracks 8 team members at TVM Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/tvm-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $7.5M–$50M |
| Series C | $10M–$55M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 30 | 29% |
| Health Care | 18 | 18% |
| Pharmaceutical | 12 | 12% |
| Software | 11 | 11% |
| Medical | 9 | 9% |

52 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 25 | 25% |
| Funding Round | 20 | 20% |
| Series C | 18 | 18% |
| Series A | 15 | 15% |
| Series D | 10 | 10% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 27 | 26% |
| Germany | 14 | 14% |
| United Kingdom | 4 | 4% |
| Italy | 2 | 2% |
| The Netherlands | 2 | 2% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Hubert Birner | General Partner | 10 | https://shizune.co/investors/profile/hubert-birner |
| Luc Marengere | Managing Partner | 10 | https://shizune.co/investors/profile/luc-marengere |
| Christoph Schröder | General Partner | 0 | https://shizune.co/investors/profile/christoph-schrder |
| Friedrich Bornikoel | Managing Director | 2 | https://shizune.co/investors/profile/friedrich-bornikoel |
| Marc Riviere | General Partner | 0 | https://shizune.co/investors/profile/marc-rivi%C3%A8re |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lamab Biologics | Lamab Biologics operates as a biotechnology company. Lamab Biologics develop first-in-class monoclonal antibody prophylactic therapeutic targeting IgE, a key mediator for allergic diseases. | $25M | Venture - Series Unknown | Feb 08, 2023 |  |
| Rapid Micro Biosystems | Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $25M | Series C | Apr 29, 2015 |  |
| Definiens | Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States. |  |  | Jun 23, 2014 |  |
| Proteon Therapeutics | Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD). | $45M | Series D | May 16, 2014 |  |
| Rapid Micro Biosystems | Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $6M |  | Apr 04, 2014 |  |
| invendo medical | invendo medical aims to become a globally leading developer and distributor of disposable, highly flexible and easy-to-use endoscopy products in the field of gastroenterology.Innovation activity in gastroenterological endoscopy has in the past decades nearly exclusively focused on the improvement of optical capabilities. However, invendomedical´s goal is to improve patient compliance and thereby increase the number of procedures performed. | $28M |  | Mar 20, 2014 |  |
| Argos Therapeutics | Argos Therapeutics, Inc., a biotechnology company, engages in developing immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The company has clinical trial programs in cancer and human immunodeficiency virus. Its products include AGS-0031 for metastatic renal cell carcinoma; AGS-0041 for HIV; CD83soluble protein for transplant rejection/autoimmune disorders; Anti IFN-alpha monoclonal antibody2 for lupus; and regulatory T cell therapy3 for autoimmune disorders. The company was formerly known as MERIX Bioscience, Inc. Argos Therapeutics was founded in 1997 and is based in Durham, North Carolina. | $17.5M | Series E | Nov 20, 2013 |  |
| F-Star Therapeutics | F-Star Therapeutics is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab:tm: antibody fragments, and bispecificantibodies, by modifying the constant region of an antibody. In particular, F-star’s Modular Antibody Technology:tm: enables rapid discovery and development of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology, F-star generates bispecific antibodies (mAb2:tm:) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates. Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture, Novo Ventures and TVM Capital; as well as from renowned strategic corporate investors: Merck Serono Ventures, MP Healthcare Venture Management and SR One. In 2013, F-star established an asset-centric vehicle structure through the formation of F-star Alpha Ltd., which included out-licensing of FS102 from F-star to F-star Alpha Ltd. In October 2014 Bristol-Myers Squibb obtained an exclusive option to buy F-star Alpha. In addition the company has alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. In 2011, F-star was selected by FierceBiotech as one of the Fierce 15 winners. F-star currently employs over 35 people at its research site in Cambridge, UK. | $9.4M | Series A | Oct 23, 2013 |  |
| Rapid Micro Biosystems | Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts. | $32.6M | Series B | Jun 26, 2013 |  |
| Definiens | Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries. Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived fromother sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives. Definiens is headquartered in Munich, Germany, and has offices throughout the United States. | $10.6M |  | Oct 01, 2012 |  |

10 of 102 investments shown.

## Co-investors
- [Skyline Ventures](https://shizune.co/investors/profile/skyline-ventures) — VC Fund, 11 deals together
- [Intersouth Partners](https://shizune.co/investors/profile/intersouth-partners) — VC Fund, 7 deals together
- [Crescendo Ventures](https://shizune.co/investors/profile/crescendo-ventures) — VC Fund, 6 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 6 deals together
- [Prism Venture Management](https://shizune.co/investors/profile/prism-venture-management) — VC Fund, 5 deals together
- [QVT Financial](https://shizune.co/investors/profile/qvt-financial) — VC Fund, 5 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Germany](https://shizune.co/investors/health-care-vc-funds-germany)
- [Biotech Investors in Germany](https://shizune.co/investors/biotech-investors-germany)
- [Biotech VC Funds in Germany](https://shizune.co/investors/biotech-vc-funds-germany)
- [Biotechnology VC Funds in Germany](https://shizune.co/investors/biotechnology-vc-funds-germany)
- [Platforms Investors in Ireland](https://shizune.co/investors/platforms-investors-ireland)
- [Biotechnology Investors in Sweden](https://shizune.co/investors/biotechnology-investors-sweden)

## FAQ

### What does TVM Capital invest in?

TVM Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Funding Round stage. Most of the 102 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is TVM Capital's check size?

TVM Capital typically joins rounds of $7.5M–$50M at Series B and $10M–$55M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TVM Capital participates in.

### How do I contact TVM Capital?

Public channels for TVM Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at TVM Capital?

The team at TVM Capital includes Hubert Birner (General Partner), Luc Marengere (Managing Partner) and Christoph Schröder (General Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co